These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 34698410

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation.
    Narang AK, Gergis C, Robertson SP, He P, Ram AN, McNutt TR, Griffith E, DeWeese TA, Honig S, Singh H, Song DY, Tran PT, DeWeese TL.
    Int J Radiat Oncol Biol Phys; 2016 Feb 01; 94(2):254-62. PubMed ID: 26853334
    [Abstract] [Full Text] [Related]

  • 6. Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis.
    Bottke D, Golz R, Störkel S, Hinke A, Siegmann A, Hertle L, Miller K, Hinkelbein W, Wiegel T.
    Eur Urol; 2013 Aug 01; 64(2):193-8. PubMed ID: 23522911
    [Abstract] [Full Text] [Related]

  • 7. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
    Huang J, Vicini FA, Williams SG, Ye H, McGrath S, Ghilezan M, Krauss D, Martinez AA, Kestin LL.
    Int J Radiat Oncol Biol Phys; 2012 Jul 15; 83(4):1141-8. PubMed ID: 22099043
    [Abstract] [Full Text] [Related]

  • 8. Gleason grading of prostate cancer in needle core biopsies: a comparison of general and urologic pathologists.
    Al-Maghrabi JA, Bakshi NA, Farsi HM.
    Ann Saudi Med; 2013 Jul 15; 33(1):40-4. PubMed ID: 23458939
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
    Flood TA, Schieda N, Keefe DT, Breau RH, Morash C, Hogan K, Belanger EC, Mai KT, Robertson SJ.
    Virchows Arch; 2016 Sep 15; 469(3):313-9. PubMed ID: 27394432
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.
    Zumsteg ZS, Zelefsky MJ, Woo KM, Spratt DE, Kollmeier MA, McBride S, Pei X, Sandler HM, Zhang Z.
    BJU Int; 2017 Nov 15; 120(5B):E87-E95. PubMed ID: 28464446
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.
    Qian Y, Feng FY, Halverson S, Blas K, Sandler HM, Hamstra DA.
    Int J Radiat Oncol Biol Phys; 2011 Nov 01; 81(3):e135-42. PubMed ID: 21345617
    [Abstract] [Full Text] [Related]

  • 16. The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading - a matched-pair analysis.
    Berg KD, Thomsen FB, Nerstrøm C, Røder MA, Iversen P, Toft BG, Vainer B, Brasso K.
    BJU Int; 2016 Jun 01; 117(6):883-9. PubMed ID: 26823232
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer.
    Sooriakumaran P, Lovell DP, Henderson A, Denham P, Langley SE, Laing RW.
    Clin Oncol (R Coll Radiol); 2005 Dec 01; 17(8):655-8. PubMed ID: 16372494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.